Commonwealth of Pennsylvania Public School Empls Retrmt SYS Invests $12.87 Million in Amgen, Inc. (AMGN) Stock

Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 69,718 shares of the medical research company’s stock, valued at approximately $12,869,000.

A number of other institutional investors have also modified their holdings of the business. Highland Capital Management LLC boosted its holdings in shares of Amgen by 1.0% in the second quarter. Highland Capital Management LLC now owns 27,457 shares of the medical research company’s stock valued at $5,068,000 after acquiring an additional 262 shares in the last quarter. Signature Wealth Management Group boosted its holdings in shares of Amgen by 12.0% in the second quarter. Signature Wealth Management Group now owns 2,603 shares of the medical research company’s stock valued at $480,000 after acquiring an additional 278 shares in the last quarter. CFO4Life Group LLC boosted its holdings in shares of Amgen by 6.5% in the second quarter. CFO4Life Group LLC now owns 4,595 shares of the medical research company’s stock valued at $848,000 after acquiring an additional 279 shares in the last quarter. Baldwin Brothers Inc. MA boosted its holdings in shares of Amgen by 0.4% in the second quarter. Baldwin Brothers Inc. MA now owns 65,971 shares of the medical research company’s stock valued at $12,178,000 after acquiring an additional 293 shares in the last quarter. Finally, Fiduciary Group LLC boosted its holdings in shares of Amgen by 1.5% in the second quarter. Fiduciary Group LLC now owns 20,118 shares of the medical research company’s stock valued at $3,714,000 after acquiring an additional 303 shares in the last quarter. 80.04% of the stock is currently owned by institutional investors.

AMGN stock opened at $195.76 on Wednesday. The stock has a market cap of $125.84 billion, a P/E ratio of 15.56, a P/E/G ratio of 1.90 and a beta of 1.36. Amgen, Inc. has a 52 week low of $163.31 and a 52 week high of $201.23. The company has a current ratio of 3.39, a quick ratio of 3.12 and a debt-to-equity ratio of 2.03.



Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, topping analysts’ consensus estimates of $3.52 by $0.31. The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.27 earnings per share. equities analysts predict that Amgen, Inc. will post 13.95 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 7th. Investors of record on Friday, August 17th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date is Thursday, August 16th. Amgen’s dividend payout ratio is currently 41.97%.

Several brokerages have recently weighed in on AMGN. Morgan Stanley lowered their target price on shares of Amgen from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, April 25th. TheStreet raised shares of Amgen from a “c+” rating to a “b-” rating in a report on Friday, May 25th. Citigroup lifted their target price on shares of Amgen from $188.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, July 30th. Piper Jaffray Companies lifted their target price on shares of Amgen from $190.00 to $210.00 and gave the company an “overweight” rating in a report on Thursday, July 26th. They noted that the move was a valuation call. Finally, Cowen reaffirmed a “buy” rating and issued a $204.00 target price on shares of Amgen in a report on Tuesday, April 24th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $202.76.

In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $195.71, for a total transaction of $298,457.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: Market Capitalization in the Stock Market

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply